INPLEX - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 282,852 | 293,378 | 361,813 | 322,745 | 242,520 | 437,706 | 643,522 | 1,155,548 |
| Profit before tax | 46,822 | 26,071 | 70,383 | 45,949 | 24,162 | 30,660 | 49,729 | -10,713 |
| Net profit | 44,481 | 24,767 | 59,817 | 41,800 | 22,954 | 24,434 | 39,734 | -10,713 |
| Equity | 52,006 | 48,899 | 73,716 | 65,516 | 48,470 | 54,697 | 74,431 | -1,282 |
| Liabilities | 79,797 | 42,034 | 59,918 | 7,306 | 26,704 | 18,390 | 123,982 | 52,304 |
| Non-current assets | 0 | 3,627 | 2,661 | 3,016 | 2,104 | 2,541 | 2,063 | 1,523 |
| Current assets | 131,773 | 87,290 | 130,973 | 69,787 | 73,022 | 70,483 | 196,260 | 49,412 |
| Total assets | 131,773 | 90,917 | 133,634 | 72,803 | 75,126 | 73,024 | 198,323 | 50,935 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 7,857 | 2,869 | 12,410 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +11.8% | +3.7% | +23.3% | -10.8% | -24.9% | +80.5% | +47.0% | +79.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 33.8% | 27.2% | 44.8% | 57.4% | 30.6% | 33.5% | 20.0% | -21.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 85.5% | 50.6% | 81.1% | 63.8% | 47.4% | 44.7% | 53.4% | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 15.7% | 8.4% | 16.5% | 13.0% | 9.5% | 5.6% | 6.2% | -0.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 16.6% | 8.9% | 19.5% | 14.2% | 10.0% | 7.0% | 7.7% | -0.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.5 | 0.9 | 0.8 | 0.1 | 0.6 | 0.3 | 1.7 | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 282,852 | 293,378 | 361,813 | 322,745 | 242,520 | 437,706 | 643,522 | 1,155,548 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
INPLEX - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-07-19 | 2026-07-20 | 162.86 |
| 2026-07-16 | 2026-07-17 | 162.86 |
INPLEX - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-03-19 | 2026-03-22 | 0.32 |
| 2025-06-19 | 2025-06-23 | 0.26 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
INPLEX, UAB (code 135483969) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In the latest financial year 2025, revenue increased to €1.16M, up 79.6% year on year and 164.0% over two years. Despite this strong top-line growth, profitability weakened materially: net profit fell to a loss of €10.7K, compared with a profit of €39.7K in 2024 and €24.4K in 2023. The profit margin therefore turned negative to -0.9% in 2025, after 6.2% in 2024 and 5.6% in 2023. The balance sheet also deteriorated, with total assets at €50.9K, equity at -€1.3K and liabilities at €52.3K at the end of 2025. Asset turnover remained high at 22.69x, reflecting significant sales relative to the asset base. Revenue per employee reached €1.16M, while profit per employee was negative in 2025, in line with the overall loss. The negative equity position makes leverage and return ratios difficult to interpret in a conventional way.